These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34922020)

  • 21. Considerations in Pfizer-BioNTech COVID-19 vaccine preparation in clinic: Quality vs quantity.
    Jin CH; Tran LM; Rivero CJ; Childs RR
    Am J Health Syst Pharm; 2022 Feb; 79(5):325-327. PubMed ID: 34634098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous reactions due to Pfizer's BNT162b2 mRNA and Moderna's mRNA-1273 vaccines.
    Oulee A; Salem S; Yahia R; Yang K; Garcia D; Holmes A; Furukawa B
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e332-e334. PubMed ID: 35028998
    [No Abstract]   [Full Text] [Related]  

  • 23. A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines.
    Banerjee S; Banerjee D; Singh A; Saharan VA
    AAPS PharmSciTech; 2022 Mar; 23(4):95. PubMed ID: 35314902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BNT162b2 COVID-19 vaccine does not affect fertility as explored in a pilot study of women undergoing IVF treatment.
    Safrai M; Kremer E; Atias E; Ben-Meir A
    Minerva Obstet Gynecol; 2024 Jun; 76(3):215-221. PubMed ID: 36193832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 Therapeutics and Vaccines: A Race to Save Lives.
    Bebenek I; Bannister R; Dubinion J; Fortin M; Liu M; Motter AL; Rohde CM; Wrzesinski C
    Toxicol Sci; 2022 Jan; 185(2):119-127. PubMed ID: 34735018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].
    Estrada-García CD; Macías-Robles AP; Cortés-Grimaldo RM; Carvajal-Alonso HL; Barreto-Alcalá M; Ramírez-Nepomuceno A; Esparza-Amaya D; Coronado-Hernández KG; Barrios-Díaz B; Campos-Téllez HH
    Rev Alerg Mex; 2023 Jan; 69(2):89-92. PubMed ID: 36928249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pool patents to get COVID vaccines and drugs to all.
    Billette de Villemeur E; Dequiedt V; Versaevel B
    Nature; 2021 Mar; 591(7851):529. PubMed ID: 33742180
    [No Abstract]   [Full Text] [Related]  

  • 31. Peter Corr outlines Pfizer's approach to innovation, maximizing capabilities and delivering essential medicine. Interview by Steve Carney.
    Corr PB
    Drug Discov Today; 2005 Aug; 10(15):1017-20. PubMed ID: 16055016
    [No Abstract]   [Full Text] [Related]  

  • 32. Lasofoxifene: CP 336156, CP-336156.
    Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan.
    Jaber HM; Ebdah S; Al Haj Mahmoud SA; Abu-Qatouseh L; Jaber YH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2333104. PubMed ID: 38584118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
    Powell J; Piszczatoski CR
    Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
    Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
    Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
    Schuhmacher A; Gassmann O; McCracken N; Hinder M
    J Transl Med; 2018 May; 16(1):119. PubMed ID: 29739427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
    Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.